sharetrader
Page 20 of 29 FirstFirst ... 10161718192021222324 ... LastLast
Results 286 to 300 of 434

Thread: PAZ Pharma Zen

  1. #286
    Membaa
    Join Date
    Nov 2004
    Location
    Paradise
    Posts
    2,798

    Default

    Quote Originally Posted by freddagg View Post
    Our ramping must be working
    11.12.18 "a few months" ago, seems to have worked a treat, especially recent months with the large seller entertaining new buyers at ever higher prices.

  2. #287
    Member
    Join Date
    Jun 2012
    Posts
    309

    Thumbs up

    Quote Originally Posted by Baa_Baa View Post
    11.12.18 "a few months" ago, seems to have worked a treat, especially recent months with the large seller entertaining new buyers at ever higher prices.
    hi woolly one
    must be the same pro as fed quacking ducks
    Wanting PLX

  3. #288
    Update Ready To Install
    Join Date
    Aug 2010
    Location
    Floating Anchor Shoals
    Posts
    8,044

    Default

    I need an interpreter for Lola

  4. #289
    Member
    Join Date
    Jun 2012
    Posts
    309

    Default

    Quote Originally Posted by Joshuatree View Post
    I need an interpreter for Lola
    Sorry Jossie but this girl is autistic. Youll have to talk with the Woolly one

  5. #290
    Member
    Join Date
    Dec 2004
    Location
    , , .
    Posts
    155

    Default

    August 1, 2019
    Press Release
    PharmaZen pre-tax profit jumps 134% to $1.83 million for the half year.
    It has taken biotechnology company PharmaZen Limited just six months to surpass its record full year result of 2018.
    Sales for the six months to June 30, jumped 50% to $8.312m from the prior year figure of $5.561m and pre-tax profit increased 134% from $785,000 to $1.839m.
    The full year 2018 result was a pre-tax profit of $1.792m on turnover of $12.573m.
    Based in Christchurch, PharmaZen is an innovative developer, manufacturer and marketer of science-based, natural, nutritional ingredients. Shares in PharmaZen are traded through the Unlisted securities trading platform.
    Managing Director Craig McIntosh described the result as being exceptionally pleasing.
    “Our 2018 result gave shareholders a glimpse of the business’s potential as our long-term investments started to come on stream. The first six months of 2019 reinforces that performance but also starts to add some magnitude to the potential,” he said.
    The full year pre-tax profit for the company was forecast at the company’s AGM to be $2.8m on turnover of $14.5m. McIntosh advised that the board of directors has since signed off an upgraded full year forecast of $3.9m pre-tax profit on $16.5m turnover.
    “While we to tend to err on the conservative side, the first six months have been well beyond expectations and it is an absolute credit to the staff and management that they have been able to accommodate such an increase.
    “Not only has the company benefited from the strong demand, but it has also had a six-month run without any major disruption with capital projects.”
    McIntosh believes this is a combination of timing and experience gained from prior projects; however, is quick to emphasise it doesn’t mean things are slowing down in terms of expansion.
    “We have the resin column plant all onsite and ready for installation and the building fitout for our finished product range is largely complete. The equipment for the facility will arrive over the next two months and will enable us to produce a complete range of finished products – soft gel oils through to hard shell capsules.”
    PharmaZen has also commenced design work for a 1,200 sqm building on their adjacent Nuttall Drive properties.
    McIntosh was reluctant to divulge what the building would be housing but confirmed it would complete the fullsite development.
    “There are a couple of gaps left in our technology portfolio that we would like to have on the current site and we are looking to move our research and development department into a purpose-built facility. This will reinforce the site as our centre of excellence while at the same time allowing expansion in other geographically advantageous locations,” he said.
    The management team has also been strengthened with the appointment of Katherine Reardon to head Sales and Marketing for consumer brands.
    “Katherine comes to us with extensive industry background and is the ideal person to assist us launch our ranges domestically and internationally.”
    The company is in the final stages of strengthening its product development function with further appointments.
    Further information : Craig McIntosh, P : (03) 337-4852 | 021-372-069

  6. #291
    Member
    Join Date
    May 2011
    Posts
    218

    Default

    An awesome result.

  7. #292
    percy
    Join Date
    Oct 2009
    Location
    christchurch
    Posts
    13,592

    Default

    Quote Originally Posted by freddagg View Post
    An awesome result.
    Yes and a fantastic upgraded outlook.
    Brought a few more for the wife at 19 cents today,as I was that impressed.

  8. #293
    Guru
    Join Date
    Jul 2002
    Location
    New Zealand.
    Posts
    2,876

    Default

    Quote Originally Posted by Arthur View Post
    August 1, 2019
    Press Release
    PharmaZen pre-tax profit jumps 134% to $1.83 million for the half year.
    It has taken biotechnology company PharmaZen Limited just six months to surpass its record full year result of 2018.
    Sales for the six months to June 30, jumped 50% to $8.312m from the prior year figure of $5.561m and pre-tax profit increased 134% from $785,000 to $1.839m.
    The full year 2018 result was a pre-tax profit of $1.792m on turnover of $12.573m.
    Based in Christchurch, PharmaZen is an innovative developer, manufacturer and marketer of science-based, natural, nutritional ingredients. Shares in PharmaZen are traded through the Unlisted securities trading platform.
    Managing Director Craig McIntosh described the result as being exceptionally pleasing.
    “Our 2018 result gave shareholders a glimpse of the business’s potential as our long-term investments started to come on stream. The first six months of 2019 reinforces that performance but also starts to add some magnitude to the potential,” he said.
    The full year pre-tax profit for the company was forecast at the company’s AGM to be $2.8m on turnover of $14.5m. McIntosh advised that the board of directors has since signed off an upgraded full year forecast of $3.9m pre-tax profit on $16.5m turnover.
    “While we to tend to err on the conservative side, the first six months have been well beyond expectations and it is an absolute credit to the staff and management that they have been able to accommodate such an increase.
    “Not only has the company benefited from the strong demand, but it has also had a six-month run without any major disruption with capital projects.”
    McIntosh believes this is a combination of timing and experience gained from prior projects; however, is quick to emphasise it doesn’t mean things are slowing down in terms of expansion.
    “We have the resin column plant all onsite and ready for installation and the building fitout for our finished product range is largely complete. The equipment for the facility will arrive over the next two months and will enable us to produce a complete range of finished products – soft gel oils through to hard shell capsules.”
    PharmaZen has also commenced design work for a 1,200 sqm building on their adjacent Nuttall Drive properties.
    McIntosh was reluctant to divulge what the building would be housing but confirmed it would complete the fullsite development.
    “There are a couple of gaps left in our technology portfolio that we would like to have on the current site and we are looking to move our research and development department into a purpose-built facility. This will reinforce the site as our centre of excellence while at the same time allowing expansion in other geographically advantageous locations,” he said.
    The management team has also been strengthened with the appointment of Katherine Reardon to head Sales and Marketing for consumer brands.
    “Katherine comes to us with extensive industry background and is the ideal person to assist us launch our ranges domestically and internationally.”
    The company is in the final stages of strengthening its product development function with further appointments.
    Further information : Craig McIntosh, P : (03) 337-4852 | 021-372-069
    Fantastic result but will it be reflected in the S P ?

  9. #294
    Guru
    Join Date
    Jul 2002
    Location
    New Zealand.
    Posts
    2,876

    Default

    Quote Originally Posted by whatsup View Post
    Fantastic result but will it be reflected in the S P ?
    Good volume ( 270k ) today.

  10. #295
    Guru
    Join Date
    Jul 2002
    Location
    New Zealand.
    Posts
    2,876

    Default

    WOW, That's interesting 500,000 @.20 worth $100 k traded on opening this morning , word must be getting out that PAZ is truly a turnaround story now.
    Well done all holders, where to from here as Im reading that there is much more to come as product line and the new facilities come on line , is there opportunities into China available with the increase in manufacturing ?

  11. #296
    Guru
    Join Date
    Jul 2002
    Location
    New Zealand.
    Posts
    2,876

    Default

    1,270,000 shares traded so far today and heading for ATH !!!

  12. #297
    percy
    Join Date
    Oct 2009
    Location
    christchurch
    Posts
    13,592

    Default

    Quote Originally Posted by whatsup View Post
    WOW, That's interesting 500,000 @.20 worth $100 k traded on opening this morning , word must be getting out that PAZ is truly a turnaround story now.
    Well done all holders, where to from here as Im reading that there is much more to come as product line and the new facilities come on line , is there opportunities into China available with the increase in manufacturing ?
    In the annual report,the outlook statement features two brands,Airoa and The 5th Quarter,both designed for the Asian markets,including China.
    Also in 1st August announcement;"the equipment for the facility will arrive over the next two months and will enable us to produce a complete range of finished products - soft gel oils through to hard shell capsules."
    Remember "traceability" and "provence".The Chinese like to buy the same NZ product that is avaliable to NZders, in NZ.Therefore we will see PAZ products Airoa and The 5th Quarter, avaliable retail here in NZ.This is why Katherine Reardon has been appointed to head sales and marketing for consumer brands.

  13. #298
    Guru
    Join Date
    Jul 2002
    Location
    New Zealand.
    Posts
    2,876

    Default

    Approx 1.2 mil shares traded today in big lines, would be very interesting to know where they are coming from and where they are going to !

  14. #299
    ShareTrader Legend Beagle's Avatar
    Join Date
    Jul 2010
    Location
    Auckland
    Posts
    13,999

    Default

    Managing Director Craig McIntosh described the result as being exceptionally pleasing
    .
    Very true and I think its a game changer so I have recently accumulated a very modest stake. Next year we will get the full years annualization of sales from the very recently released Airoa product range as well as a the 5th quarter range to be released later this year. Forecast forward PE for YE 31/12/2019 at 20 cents is just 15.7. When one reflects on that and the rate of growth, some of the overt optimism previously expressed on here appears to be well founded.
    Last edited by Beagle; 06-08-2019 at 08:09 AM.
    No butts, hold no mutts, (unless they're the furry variety).

  15. #300
    Junior Member
    Join Date
    Nov 2013
    Posts
    8

    Default

    Forgive me if this is covered elsewhere: Is 20,000 shares the initial purchase minimum?

Bookmarks

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •